Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ColoDix

Financiado

Disruptive and high accuracy test for early colorectal cancer detection in blood

AMADIX is a leading molecular diagnostics company, led by Rocío Arroyo, focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. Colorectal cancer (CRC) is the 2nd leading cause of canc... ver más

31/07/2024

ADVANCED MARKER DI...

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

ADVANCED MARKER DISCOVERY La investigación, el desarrollo, la producción, la comercialización y la distribución e importación de productos biotecnológicos, farmacéuti...

TRL 3-4 | 4M€

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-07-31

HORIZON-EIC-2021-ACCELERATORCHALLENGES-01-01: Strategic Digital and Health Techno... Scope:The EIC Accelerator Challenges supports companies (principally start-ups and SMEs) to scale up...

I+D

Cerrada hace 2 años

0% 70% 100%

1 Participantes

ADVANCED MARKER DISCOVERY

2.50M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

DIN2018-009704 Validación analítica y preclínica de un test pronóstico de r... 56K€ Cerrado

FJC2019-039770-I Liquid biopsy mutant allele fractions as novel biomarkers fo... 50K€ Cerrado

PANCAID PANcreatic CAncer Initial Detection via liquid biopsy 10M€ Cerrado

PTQ-08-03-08047 Generación de proteínas recombinantes y anticuerpos de inter... 63K€ Cerrado

DI-16-08951 Determinación de perfiles metabolómicos y de miRNAs en biops... 65K€ Cerrado

CTQ2015-64402-C2-1-R NUEVAS PLATAFORMAS DE MULTIPLEXADO ELECTROANALITICAS PARA LA... 249K€ Cerrado

Duración del proyecto: 24 meses Fecha Inicio: 2022-07-22
Fecha Fin: 2024-07-31

Líder del proyecto

ADVANCED MARKER DISCOVERY La investigación, el desarrollo, la producción, la comercialización y la distribución e importación de productos biotecnológicos, farmacéuti...

TRL 3-4 | 4M€

Presupuesto del proyecto 4M€

Descripción del proyecto AMADIX is a leading molecular diagnostics company, led by Rocío Arroyo, focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. Colorectal cancer (CRC) is the 2nd leading cause of cancer-related deaths worldwide. Most of these cancers and deaths could have been prevented by increasing the use of recommended screening tests that detect premalignant lesions, called advanced adenomas. Colonoscopy is the gold standard screening method, although it is an invasive and expensive procedure. AMADIX has previously developed an innovative blood-based test for CRC diagnosis (ColoFast), based on an initial combination of cutting-edge biomarkers (micro-RNAs) and validated in +1,000 samples. Indicated to screen healthy population from 50 to 85 years old,has shown superior performance in early cancer detection than any of the tests commercialized, better compliance and cost-effectiveness and is being validated in a European prospective study with 3,100 patients (recruitment concluded) granted by SME Phase 2 with €2.8M. AMADIX has identified new promising biomarkers to be incorporated to the initial signature, to improve the diagnostic performance. AMADIX has taken advantage of the potential of Artificial Intelligence and Big Data to identify CRC risk factors from the patients’ clinical records and develop diagnostic prediction models. Our goal is to validate this new signature, ColoDix, more accurate than the initial combination, based on different types of biomarkers, followed by its commercialization as LDT and as IVD kit. In addition, a risk factors-based algorithm will be incorporated, enabling to predict and identify individuals with a high risk of developing CRC or premalignant polyps, even if they are younger than 50 years old, improving their survival consequently. AMADIX expects to reach between 2023-2032 accumulated revenues of €1,997M from the commercialization of ColoDix in Europe and USA.

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores